Developing a vaccine to generate broad immunity against HIV
Official title: Combining membrane Env vaccine regimens to elicit multiple bnAb lineages and consistent cross-neutralization of HIV
Funded at Scripps Research Institute, the · NIH-10977071 · Data updated 2026-11-12
This study is working on a new HIV vaccine that helps your body make stronger defenses against the virus, using a special method to boost your immune system, and it could lead to a more effective way to protect you from HIV with fewer shots.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Scripps Research Institute, the NIH-funded |
| Lab location | 1 site (La Jolla, United States) |
| Project start | December 1, 2023 |
| Project end | October 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $912,596 |
| NIH project number | 5R01AI181784-02 |
| Project ID | NIH-10977071 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals at high risk for HIV infection or those who are HIV-negative but may benefit from preventive measures.
✕Less likely to help
Patients who are already HIV-positive or those with compromised immune systems may not benefit from this research.
What this research studies
This research focuses on creating a preventative vaccine for HIV that aims to stimulate the immune system to produce broadly neutralizing antibodies (bnAbs). By using innovative germline targeting (GT) protocols, the study seeks to activate specific B-cell precursors in the body to enhance their ability to fight HIV. The approach involves using a new liposome platform that has shown promise in animal models, aiming to improve the efficiency of the vaccine and its ability to elicit a strong immune response with fewer doses. Patients may benefit from this research as it could lead to a more effective HIV vaccine that provides long-lasting protection.
Why it matters
Potential benefit: If successful, this research could lead to a highly effective HIV vaccine that significantly reduces the risk of infection.
How similar studies have gone: Previous research has shown promise in developing vaccines that elicit bnAbs, but this approach is innovative and aims to improve upon existing methods.
Where this research is happening
-
Scripps Research Institute, the
La Jolla, United States Active
Researchers
- Principal investigator: Zwick, Michael B — Scripps Research Institute, the
- Study coordinator: Zwick, Michael B
Related research
Other NIH-funded projects on the same topics.
-
The Participant Center helps people join and stay in a nationwide health study
A nationwide program to support people in joining, contributing biosamples, and staying connected to a large health study in the United States.
-
Data Sharing and Bioinformatics Core for Viral Systems Biology
A center-led effort to manage, share, and interpret large viral systems biology data using open tools and a community-friendly portal.
-
Germline-targeted HIV vaccines using membrane liposome tech to trigger bnAbs
A new HIV vaccine approach aims to spark broadly neutralizing antibodies by showing MPER on membranes, tested in models and early studies to guide future human trials.
-
Antivirals for hemorrhagic fever viruses like LASV, SFTSV, and EBOV
A multi-institutional effort to find and validate antiviral compounds that block key viral proteins from LASV, SFTSV, and EBOV to help people at risk from serious hemorrhagic fevers.
-
Developing new antivirals for flaviviruses
A research team is working to create oral antiviral drugs targeting flaviviruses to treat infections that affect millions of people.
-
CoV inhibitors targeting non-enzymatic SARS-CoV-2 components
A multicenter research effort seeks antiviral ideas that block SARS-CoV-2 parts that don’t work through traditional enzymes, aiming to help people affected by COVID-19.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.